Eflornithine for medulloblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Jan 2021: Trial registered, NCT04696029
  2. 29 Mar 2021: Trial started, NCT04696029

The trials

NCT04696029: DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

State
Under way
Phase
Phase 2
People
118 planned
Started
29 Mar 2021
Primary completion
Mar 2028
Arms
Difluoromethylornithine (DFMO)
Results
None posted
  1. 6 Jan 2021: Trial registered
  2. 29 Mar 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Difluoromethylornithine.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.